Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

The USFDA accepted Zydus and Formycon’s BLA for FYB206, a proposed Keytruda biosimilar, for review; the application was submitted in Q3 2026 and a decision could come in Q3 2027. The companies say FYB206 was developed without a comparative Phase III efficacy trial under a pathway agreed with the FDA in early 2025. Zydus holds exclusive US and Canada commercialization rights, subject to approval and resolution of intellectual-property issues; Formycon is entitled to a milestone payment. Keytruda and Keytruda Qlex generated $31.7 billion in worldwide sales in 2025.

Analysis

The key signal is regulatory de-risking, not a near-term earnings shock. FDA filing acceptance validates that the application can enter substantive review; it does not establish biosimilarity, predict approval, or resolve the intellectual-property issues that could govern launch timing. The agreed no-Phase-III pathway may lower development cost and shorten the path, but also concentrates scrutiny on analytical, pharmacokinetic, manufacturing and immunogenicity evidence. Any deficiency or request for additional data could reset the timeline.

For FYB, the milestone payment is near-term support, while meaningful economics remain contingent on approval, launch access and supply execution. Formycon’s upside is leveraged to partner commercialization and its gross-profit participation, but investors should verify the milestone amount, remaining development obligations, supply capacity and financing runway before underwriting earnings contribution. Zydus has the commercial role in North America, but the announcement alone does not establish launch economics or uptake.

For MRK, this is a long-dated patent-erosion signal, not a reason to extrapolate immediate Keytruda revenue loss. The offset is Merck’s ability to manage lifecycle and contracting, including its subcutaneous formulation; biosimilar substitution depends on final labeling, payer/provider economics, supply reliability and IP resolution. Oncology adoption may be slower and more indication-specific than headline biosimilar market-share assumptions imply.

Contrarian view: the first-mover framing may overstate commercial advantage; acceptance is procedural, and competitors can still reach market before FYB if their regulatory or IP path is faster. Near term, avoid shorting MRK solely on this filing event. Reassess after FDA review signals, patent litigation developments and evidence of payer contracting. The thesis weakens if FYB faces a major information request, approval is delayed, IP blocks launch, or Merck’s lifecycle strategy materially limits substitution.

Key Decisions for Investors

• FYB (Formycon): Treat as a catalyst-driven, high-binary-risk position rather than a near-term earnings compounder. Consider adding only on weakness and with position size capped to tolerate a review delay or IP-related launch deferral; verify milestone value, cash runway and supply readiness first.
• MRK: No event-driven short recommendation. Monitor patent/IP rulings and any evidence that payer or provider contracting is shifting ahead of approval; a short thesis needs a credible launch timeline and measurable erosion in Keytruda demand, not filing acceptance alone.
• Set a 1–3 month watch for FDA information requests, regulatory updates, and disclosed IP or commercialization milestones. For a 6–18 month thesis, track approval timing, launch rights, manufacturing readiness, and early payer/provider access evidence; absence of these would argue against pricing in rapid FYB uptake.
• Do not assign a commercial value to FYB from the addressable market headline alone. Revisit only when the companies disclose the milestone amount, remaining investment needs, product supply terms, and launch economics.